Drugs / DV-10
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07544589 | Apr 2026 → Apr 2046 expected | biliary tract cancer, colorectal cancer, esophageal adenocarcinoma, gastric adenocarcinoma +1 | Dispatch Biotherapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-08-06 | Dispatch Biotherapeutics | Regulatory Dispatch Bio Announces First Patient Dosed in Phase 1 Study of DISP-10, a Novel Investigational Immunotherapy, in Advanced Gastrointestinal (GI) Cancers dispatchbio.com ↗
Additionally, DISP-10 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of advanced GI cancers. |
| 2026-01-12 | Dispatch Biotherapeutics | Regulatory Dispatch Bio Announces FDA Clearance of IND Application for DISP-10, a First-in-Class Immunotherapy Treatment, in Solid Tumors dispatchbio.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-08-06 | Dispatch Biotherapeutics | Dispatch Bio Announces First Patient Dosed in Phase 1 Study of DISP-10, a Novel Investigational Immunotherapy, in Advanced Gastrointestinal (GI) Cancers dispatchbio.com ↗ |
| 2026-01-12 | Dispatch Biotherapeutics | Dispatch Bio Announces FDA Clearance of IND Application for DISP-10, a First-in-Class Immunotherapy Treatment, in Solid Tumors dispatchbio.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DV-10 | “DISP-10, a combination therapy consisting of DV-10 (adenovirus) and idecabtagene vicleucel” NCT07544589 ↗ |